The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson and technology editor/analyst Andrew Tonner discuss topics across the investing world.
In today's edition, David changes his opinion on high-dividend payer AstraZeneca. After a number of drugs failed in clinical trials and a recent rejection by the FDA for a diabetes drug, AstraZeneca's already troubled pipeline looks even less prepared to deal with the "patent cliff." David believes management may feel inclined to make an acquisition, putting in jeopardy the company's strong balance sheet and dividend.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
At the time thisarticle was published Andrew Tonner has no positions in the stocks mentioned above. David Williamson owns shares of Pfizer. The Motley Fool owns shares of AstraZeneca plc (ADR).Motley Fool newsletter services recommendPfizer. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.